TY - JOUR
T1 - Cannabis use is associated with low plasma endocannabinoid Anandamide in individuals with psychosis
AU - Bassir Nia, Anahita
AU - Gibson, Claire L.
AU - Spriggs, Sharron A.
AU - Jankowski, Samantha E.
AU - DeFrancisco, Daniel
AU - Swift, Amy
AU - Perkel, Charles
AU - Galynker, Igor
AU - Honrao, Chandrashekhar
AU - Makriyannis, Alexandros
AU - Hurd, Yasmin L.
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project was generously supported by the National Institutes of Health TL1 grant, TR001434 and internal Mount Sinai funds from the Addiction Institute (YLH). Anahita Bassir Nia was supported by the National Institute of Health K12 DA000167 grant.
Publisher Copyright:
© The Author(s) 2023.
PY - 2023/5
Y1 - 2023/5
N2 - Background: Cannabis use suppresses the endocannabinoid system in healthy individuals. However, the association between cannabis use with the endocannabinoid system is understudied in individuals with psychosis despite the high rate of cannabis use in these individuals. Methods: We enrolled 83 individuals who were admitted to an inpatient psychiatric unit with psychotic presentations, and measured their plasma levels of main endocannabinoids, Anandamide (AEA) and 2-Acylglycerol (2-AG), and endocannabinoid related compounds, Palmitoylethanolamine, and N-oleoylethanolamine. Cannabis use was assessed with urine toxicology and frequency of cannabis use was assessed using self-reported questionnaires. The Positive and Negative Syndrome Scale was used to assess the severity of psychotic symptoms. Results: Overall, we had 38 individuals in cannabis positive group (CN+) and 45 individuals in cannabis negative group (CN−). Compared to CN−, CN+ group had lower plasma levels of AEA, which remained significant after controlling for age, gender, race/ethnicity, and use of other drugs. Conclusion: Cannabis use is associated with low plasma AEA levels in individuals with psychosis, which is in the same line with reported suppressive effects of cannabis on the endocannabinoid system in healthy individuals. Further studies are needed to investigate the clinical significance of this finding.
AB - Background: Cannabis use suppresses the endocannabinoid system in healthy individuals. However, the association between cannabis use with the endocannabinoid system is understudied in individuals with psychosis despite the high rate of cannabis use in these individuals. Methods: We enrolled 83 individuals who were admitted to an inpatient psychiatric unit with psychotic presentations, and measured their plasma levels of main endocannabinoids, Anandamide (AEA) and 2-Acylglycerol (2-AG), and endocannabinoid related compounds, Palmitoylethanolamine, and N-oleoylethanolamine. Cannabis use was assessed with urine toxicology and frequency of cannabis use was assessed using self-reported questionnaires. The Positive and Negative Syndrome Scale was used to assess the severity of psychotic symptoms. Results: Overall, we had 38 individuals in cannabis positive group (CN+) and 45 individuals in cannabis negative group (CN−). Compared to CN−, CN+ group had lower plasma levels of AEA, which remained significant after controlling for age, gender, race/ethnicity, and use of other drugs. Conclusion: Cannabis use is associated with low plasma AEA levels in individuals with psychosis, which is in the same line with reported suppressive effects of cannabis on the endocannabinoid system in healthy individuals. Further studies are needed to investigate the clinical significance of this finding.
KW - Psychosis
KW - anandamide
KW - cannabis
KW - endocannabinoid
UR - http://www.scopus.com/inward/record.url?scp=85146595356&partnerID=8YFLogxK
U2 - 10.1177/02698811221148604
DO - 10.1177/02698811221148604
M3 - Article
C2 - 36633290
AN - SCOPUS:85146595356
SN - 0269-8811
VL - 37
SP - 484
EP - 489
JO - Journal of Psychopharmacology
JF - Journal of Psychopharmacology
IS - 5
ER -